News
NVO
41.63
+2.41%
0.98
Novo Nordisk Earnings Call Signals Recovery Amid Headwinds
TipRanks · 2h ago
Novo Nordisk Says Wegovy May Help Reduce 'Food Noise' In Adults With Obesity
NASDAQ · 4h ago
Novo Nordisk Reports Strong Weight-Loss Results In Phase 3 REDEFINE 9 Trial Of CagriSema
NASDAQ · 4h ago
GLP-1s can save health system money if priced below $350 a month: analysis
Seeking Alpha · 8h ago
Novo Nordisk vs. Pfizer: Does a Weight Loss or Cancer Focused Pharma Stock Make a Better Buy for 2027?
The Motley Fool · 13h ago
Novo Nordisk (NVO) Could Be 46% Undervalued After Wegovy Pill Prescription Focus
Simply Wall St · 21h ago
Novo Nordisk Secures EU Approval For FREHEMGO In Haemophilia A
NASDAQ · 1d ago
Viking Therapeutics gains amid report of renewed takeover interest
Seeking Alpha · 1d ago
Novo Nordisk Scores EU Win For Hemophilia Drug, Advances Sickle Cell Treatment Toward Approval
Benzinga · 1d ago
Cboe data shows mixed options sentiment in Novo Nordisk with shares up 0.65%
TipRanks · 1d ago
Novo Nordisk submits etavopivat NDA to FDA, etavopivat MAA to EMA
TipRanks · 1d ago
Novo Nordisk Submits FDA New Drug Application And EMA Marketing Authorization Application For Etavopivat For Treatment Of Adolescents And Adults With Sickle Cell Disease
Benzinga · 1d ago
Berenberg Bank Reaffirms Their Hold Rating on Novo Nordisk (0QIU)
TipRanks · 1d ago
Prediction: $10,000 Invested in Viking Therapeutics Before Its Oral Phase 3 Readouts Could Be Worth This Much by 2028
The Motley Fool · 1d ago
Novo Nordisk's CagriSema Launch in Focus -- Market Talk
Dow Jones · 1d ago
Vivani Medical Advances Long-Acting Semaglutide Implant Toward Phase 2 Trial in 2027
Benzinga · 2d ago
Eli Lilly Stock (LLY) Jumps as China Approves Its Weight-Loss Pill
TipRanks · 2d ago
Blackstone Is Paying Up to $1.5 Billion for Pfizer’s Answer to Wegovy
24/7 Wall St. · 2d ago
Novo and DJ Khaled team up to take fans behind the scenes of the iconic musician's real-life "Walk, Golf, and Wegovy®" diet and weight-loss routine
PR Newswire · 2d ago
Hims & Hers Bounced Back 9%, But Its Earnings Reveal a Costly Trade-Off
NASDAQ · 2d ago
More
Webull provides a variety of real-time NVO stock news. You can receive the latest news about Novo-Nordisk A/S through multiple platforms. This information may help you make smarter investment decisions.
About NVO
Novo Nordisk A/S is a global healthcare company engaged in diabetes care. The Company is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The Company operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The Company's diabetes and obesity care segment covers insulin, GLP-1, other protein-related products, such as glucagon, protein-related delivery systems and needles, and oral anti-diabetic drugs. The Company's biopharmaceuticals segment covers the therapy areas of hemophilia care, growth hormone therapy and hormone replacement therapy. The Company also offers Saxenda product to treat obesity. It offers a range of products, including NovoLog/NovoRapid; NovoLog Mix/NovoMix; Prandin/NovoNorm; NovoSeven; Norditropin, and Vagifem. As of December 31, 2016, it marketed its products in over 180 countries. Its regional structure consists of two commercial units: North America and International Operations.